TruSight Oncology Comprehensive
Illumina, Inc. · Decision date Jun 26, 2026
What did the FDA approve?
FDA records P230011/S002 as a supplement to PMA P230011, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jun 26, 2026.
FDA approval order statement
TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score and Microsatellite Instability (MSI) status. The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Jun 26, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230011/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Illumina, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Jun 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Illumina, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230011 · Original PMA
TruSight Oncology Comprehensive
P230011/S002 received
Application receipt date recorded by FDA.
P230011/S004 · Related supplement
TruSight Oncology Comprehensive
P230011/S005 · Related supplement
TruSight Oncology Comprehensive
P230011/S007 · Related supplement
TruSight Oncology Comprehensive
P230011/S002 · FDA decision
Normal 180 Day Track
P230011/S006 · Related supplement
TruSight Oncology Comprehensive
P230011/S008 · Related supplement
TruSight Oncology Comprehensive
Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Illumina, Inc. | PMA approval | Aug 21, 2024 | FDA | |
TruSight Oncology ComprehensiveP230011/S004 | Illumina, Inc. | PMA supplement | Sep 5, 2025 | FDA |
TruSight Oncology ComprehensiveP230011/S005 | Illumina, Inc. | PMA supplement | Sep 19, 2025 | FDA |
TruSight Oncology ComprehensiveP230011/S007 | Illumina, Inc. | PMA supplement | Apr 23, 2026 | FDA |
TruSight Oncology ComprehensiveP230011/S006 | Illumina, Inc. | PMA supplement | Aug 14, 2026 | FDA |
TruSight Oncology ComprehensiveP230011/S008 | Illumina, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Illumina, Inc.
- Headquarters
- Not reported
- Brand website
- illumina.com
- FDA applicant address
- 5200 Illumina Way, San Diego, CA, 92122
Sources and methodology
- Original FDA record: P230011/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





